Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis

Company Overview

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $1.68 to $1.90
• 50-Day Range: $1.31 to $1.82
• 52-Week Range: $0.98 to $9.21
• Volume: 437,500 shs
• Average Volume: 250,384 shs
• Market Capitalization: $60.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.50
• Consensus Rating: Hold

RPHM Stock Analysis - Frequently Asked Questions

How were Reneo Pharmaceuticals' earnings last quarter?

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) posted its earnings results on Monday, March, 27th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.03.

When did Reneo Pharmaceuticals IPO?

Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Who are Reneo Pharmaceuticals' major shareholders?

Top institutional shareholders of Reneo Pharmaceuticals include BML Capital Management LLC (10.34%), Ikarian Capital LLC (3.07%), Vestal Point Capital LP (2.39%) and Geode Capital Management LLC (0.64%). Insiders that own company stock include Braden Michael Leonard, Holdings A/S Novo, Niall O'donnell, Ashley Hall and Michael Cruse.
View institutional ownership trends.

What other stocks do shareholders of Reneo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Reneo Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Invesco QQQ (QQQ), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

• Last Earnings: 3/27/2023
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RPHM
• CUSIP: N/A
• CIK: 1637715
• Web: reneopharma.com
• Phone: 858-283-0280
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.50
• High Stock Price Target: $1.50
• Low Stock Price Target: $1.50
• Potential Upside/Downside: -17.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-77,390,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.52%
• Return on Assets: -56.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 57.86
• Quick Ratio: 57.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.66 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 33,430,000
• Free Float: 27,439,000
• Market Cap: $60.84 million
• Optionable: Optionable
• Beta: 0.21